GE HealthCare is taking the lead industrial role in PREDICTOM, a €21 million consortium project that brings together 30 partners from academia, business, civil society, and hospitals in 15 countries to develop an AI-screening platform to identify individuals at risk of developing Alzheimer’s disease.
The project is part of the Innovative Health Initiative (IHI), a public-private partnership between the European Union and the European life science industries, began on 1 November 2023 and will run until 31 October 2027.
Led by Stavanger University Hospital in Norway, the PREDICTOM project aims to develop a digital platform that will aggregate data from participant at different screening stages of screening, including imaging, blood, cerebrospinal fluid, electrophysiological, and digital biomarkers. The platform will then use AI algorithms to analyze the data from all biomarkers and generate risk assessments, early diagnoses, and prognosis, which will lay the foundation for early detection and treatment. By improving the ease of identification of those with early signs of dementia, the PREDICTOM project hopes to have a significant impact on the personal and economic burden of dementia in Europe and across the world.
GE HealthCare’s digital teams in Budapest will develop the platform and AI algorithms, while its Magnetic Resonance (MR) Research team in Munich will work with the clinical partners to identify MR biomarkers that could be indicative of early stages of Alzheimer disease.
GE HealthCare is committed to building a comprehensive eco system across the cardiology, oncology, and neurology care pathways, and personalize the patient journey, aiming to support the entire care area across diagnosis, therapy planning and delivery, and monitoring with its comprehensive suite of products and solutions.
To view the source version, please click HERE.